Computer modeling identified a natural compound as a potential drug for treating cannabis withdrawal
Using computational drug design tools, researchers identified stemphol (a naturally occurring compound) as a promising CB1 receptor ligand candidate for treating cannabis withdrawal syndrome.
Quick Facts
What This Study Found
Researchers used computational chemistry tools to screen for potential drug candidates to treat cannabis withdrawal syndrome, focusing on compounds that could interact with the CB1 cannabinoid receptor. Among the candidates evaluated, stemphol (ZINC1730183, also known as 2-n-butyl-5-n-pentylbenzene-1,3-diol) showed favorable predictions both as a human CB1 ligand and for synthetic accessibility.
The approach was based on analyzing natural ligands of the CB1 receptor to identify structural features that could be replicated in drug candidates.
Key Numbers
Lead compound: stemphol (ZINC1730183). Positive predictions for: CB1 receptor binding and synthetic accessibility.
How They Did This
In silico (computational) drug design using molecular modeling, docking simulations, and ADMET (absorption, distribution, metabolism, excretion, toxicity) predictions. No experimental validation was performed.
Why This Research Matters
Cannabis withdrawal syndrome is recognized in the DSM-5 but has few effective pharmacological treatments. This computational approach represents an early step toward identifying new drug candidates that could target the CB1 receptor to manage withdrawal symptoms.
The Bigger Picture
Drug discovery for cannabis withdrawal is in its infancy. Computational approaches can rapidly screen large numbers of potential compounds, narrowing the field before expensive experimental testing. Stemphol's identification as a candidate scaffold is a starting point for further medicinal chemistry optimization.
What This Study Doesn't Tell Us
Purely computational study with no experimental validation. In silico predictions do not guarantee in vivo activity. The compound has not been tested for CB1 binding, pharmacological activity, or therapeutic efficacy. The gap between computational prediction and clinical drug is vast.
Questions This Raises
- ?Does stemphol actually bind to CB1 receptors when tested experimentally?
- ?Would CB1 modulation be the best pharmacological approach to cannabis withdrawal?
- ?How far is stemphol from being a viable drug candidate?
Trust & Context
- Key Stat:
- Stemphol identified computationally as a CB1 ligand candidate for withdrawal treatment
- Evidence Grade:
- Purely computational study. Represents the earliest stage of drug discovery with no experimental confirmation.
- Study Age:
- Published in 2017. Whether stemphol has progressed to experimental testing is not documented in subsequent literature.
- Original Title:
- Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa.
- Published In:
- ChemMedChem, 12(16), 1408-1416 (2017)
- Authors:
- Ferreira, Jaderson V, Chaves, Gisele A, Marino, Bianca L B, Sousa, Kessia P A, Souza, Lucilene R, Brito, Maiara F B, Teixeira, Hueldem R C, da Silva, Carlos H T P, Santos, Cleydson B R, Hage-Melim, Lorane I S
- Database ID:
- RTHC-01377
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Could this lead to a withdrawal medication?
The computational predictions are a first step, but translating a predicted compound into an actual medication requires years of experimental testing, animal studies, and clinical trials. Most computationally identified candidates do not become drugs.
What is stemphol?
Stemphol is a naturally occurring compound (2-n-butyl-5-n-pentylbenzene-1,3-diol) that the computational analysis predicted would bind to CB1 cannabinoid receptors. It was identified as having both predicted activity and the ability to be synthesized in the laboratory.
Read More on RethinkTHC
- 30-days-without-weed
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- anger-irritability-quitting-weed-withdrawal
- appetite-after-quitting-weed
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- caffeine-weed-withdrawal
- cannabinoid-hyperemesis-syndrome
- cannabis-withdrawal-complete-guide
- cannabis-withdrawal-severity-levels-mild-moderate-severe
- cannabis-withdrawal-syndrome
- cannabis-withdrawal-syndrome-dsm-5
- cannabis-withdrawal-syndrome-timeline-day-by-day
- cannabis-withdrawal-vs-alcohol-nicotine-opioid-comparison
- creativity-without-weed-quitting-artist-musician
- emotional-after-quitting-weed-crying
- first-week-quitting-weed
- hobbies-after-quitting-weed
- how-long-does-weed-withdrawal-last
- how-long-to-feel-normal-after-quitting-weed
- identity-after-quitting-weed
- leaving-stoner-culture-identity
- marijuana-withdrawal-symptoms
- money-saved-quitting-weed-calculator
- night-sweats-quitting-weed-withdrawal
- one-year-sober-weed
- paws-cannabis-post-acute-withdrawal
- quitting-weed-creativity
- quitting-weed-face-changes-skin
- quitting-weed-weight-loss-gain
- weed-cravings
- weed-depersonalization-derealization
- weed-paws-withdrawal
- weed-withdrawal-anger
- weed-withdrawal-brain-fog
- weed-withdrawal-chest-tightness-heart-palpitations
- weed-withdrawal-crying-emotional
- weed-withdrawal-depression
- weed-withdrawal-headaches
- weed-withdrawal-irritability
- weed-withdrawal-men
- weed-withdrawal-mood-swings
- weed-withdrawal-nausea
- weed-withdrawal-night-sweats
- weed-withdrawal-no-appetite
- weed-withdrawal-sweating-detox
- weed-withdrawal-timeline
- weed-withdrawal-vs-alcohol
- weed-withdrawal-women
- what-happens-when-you-stop-smoking-weed
Cite This Study
https://rethinkthc.com/research/RTHC-01377APA
Ferreira, Jaderson V; Chaves, Gisele A; Marino, Bianca L B; Sousa, Kessia P A; Souza, Lucilene R; Brito, Maiara F B; Teixeira, Hueldem R C; da Silva, Carlos H T P; Santos, Cleydson B R; Hage-Melim, Lorane I S. (2017). Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa.. ChemMedChem, 12(16), 1408-1416. https://doi.org/10.1002/cmdc.201700129
MLA
Ferreira, Jaderson V, et al. "Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa.." ChemMedChem, 2017. https://doi.org/10.1002/cmdc.201700129
RethinkTHC
RethinkTHC Research Database. "Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic P..." RTHC-01377. Retrieved from https://rethinkthc.com/research/ferreira-2017-cannabinoid-type-1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.